Cypherpunk Technologies (CYPH) Projected to Post Quarterly Earnings on Wednesday

Cypherpunk Technologies (NASDAQ:CYPH) is anticipated to announce its results before the market opens on Wednesday, March 25th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.

Cypherpunk Technologies Trading Up 1.2%

NASDAQ:CYPH opened at $0.71 on Tuesday. The stock has a 50 day moving average of $0.73 and a 200-day moving average of $0.87. The firm has a market capitalization of $64.16 million, a PE ratio of 10.19 and a beta of -0.15. Cypherpunk Technologies has a 52 week low of $0.22 and a 52 week high of $3.70.

Wall Street Analyst Weigh In

CYPH has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Cypherpunk Technologies in a research report on Thursday, January 22nd. Wall Street Zen raised Cypherpunk Technologies from a “sell” rating to a “hold” rating in a research report on Tuesday, November 25th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Reduce”.

Institutional Trading of Cypherpunk Technologies

Several institutional investors have recently modified their holdings of CYPH. Acadian Asset Management LLC boosted its stake in Cypherpunk Technologies by 470.4% during the first quarter. Acadian Asset Management LLC now owns 1,280,531 shares of the company’s stock valued at $389,000 after buying an additional 1,056,047 shares in the last quarter. Geode Capital Management LLC bought a new stake in Cypherpunk Technologies in the fourth quarter worth about $615,000. State Street Corp acquired a new stake in Cypherpunk Technologies in the 4th quarter valued at about $163,000. HighTower Advisors LLC acquired a new stake in Cypherpunk Technologies in the 4th quarter valued at about $59,000. Finally, LPL Financial LLC bought a new position in shares of Cypherpunk Technologies during the 4th quarter valued at about $38,000. Institutional investors and hedge funds own 30.46% of the company’s stock.

About Cypherpunk Technologies

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.